Prestige Consumer Healthcare Inc. (PBH) Stock Forecast
PBH analyst forecast
as of October 18, 2026- Analyst consensus
- Buy 4.29 / 5 from 7 analysts
- Price target
- $67.80 average of analyst targets
- Upside to target
- +35.8% from the latest close
- Next earnings
- November 5, 2026 EPS estimate $1.06
- 52-week range
- $44.77 – $70.21
PBH analyst ratings
7 analystsNumber of analysts at each rating.
PBH price target
The average of analyst 12-month price targets compared with the latest close and the 52-week range.
PBH earnings per share estimates
| Period | Average | Low | High | Year ago | Growth | Analysts |
|---|---|---|---|---|---|---|
| Current quarter (Sep '26) | $1.07 | $1.05 | $1.08 | $0.86 | +24.2% | 7 |
| Next quarter (Dec '26) | $1.24 | $1.20 | $1.31 | $1.14 | +8.9% | 7 |
| Current fiscal year (FY2027) | $4.57 | $4.45 | $4.63 | $4.38 | +4.3% | 8 |
| Next fiscal year (FY2028) | $5.08 | $4.72 | $5.35 | $4.57 | +11.2% | 8 |
Consensus EPS estimates; growth compares the average estimate with the year-ago EPS.
PBH revenue estimates
| Period | Average | Low | High | Growth | Analysts |
|---|---|---|---|---|---|
| Current quarter (Sep '26) | $329.1M | $328.6M | $330.4M | +20.1% | 7 |
| Next quarter (Dec '26) | $353.1M | $347.5M | $368.7M | +24.6% | 7 |
| Current fiscal year (FY2027) | $1.27B | $1.11B | $1.31B | +17.0% | 8 |
| Next fiscal year (FY2028) | $1.35B | $1.12B | $1.40B | +6.1% | 8 |
PBH EPS: reported and forecast
Fiscal years; "E" marks estimates, the line shows the range from the lowest to the highest estimate.
PBH revenue: reported and forecast
PBH EPS estimate revisions
| Period | 90 days ago | 60 days ago | 30 days ago | 7 days ago | Now | Change (90 d) | Revisions (30 d) |
|---|---|---|---|---|---|---|---|
| Current quarter (Sep '26) | $1.10 | $1.15 | $1.07 | $1.07 | $1.07 | −2.9% | 0 up · 1 down |
| Next quarter (Dec '26) | $1.25 | $1.24 | $1.24 | $1.24 | $1.24 | −0.7% | 0 up · 2 down |
| Current fiscal year (FY2027) | $4.57 | $4.57 | $4.57 | $4.57 | $4.57 | −0.1% | 1 up · 1 down |
| Next fiscal year (FY2028) | $5.01 | $4.95 | $5.08 | $5.08 | $5.08 | +1.4% | 1 up · 0 down |
How the consensus EPS estimate changed over the last 90 days, and how many analysts raised or lowered it in the last 30 days.
PBH earnings surprises
Reported EPS vs the consensus estimate for the last 12 quarters; PBH beat in 7 of 12.
What analysts expect from PBH
7 analysts cover Prestige Consumer Healthcare; their consensus rating is buy (4.29 on a 1–5 scale, where 5 is a strong buy). The average price target is $67.80, 35.8% above the latest close of $49.92. Analysts expect earnings of $4.57 per share for FY2027, +4.3% from a year earlier. For FY2028 the average estimate is $5.08 per share on revenue of $1.4 billion. Prestige Consumer Healthcare beat the EPS estimate in 7 of the last 12 quarters.
Related: PBH income statement, PBH key metrics, PBH chart. See the PBH stock overview for the latest quote and news.
PBH forecast FAQ
What is Prestige Consumer Healthcare's price target?
The average analyst price target for Prestige Consumer Healthcare is $67.80, 35.8% above the latest close of $49.92.
Is Prestige Consumer Healthcare a buy, hold or sell?
Of 7 analysts covering Prestige Consumer Healthcare, 4 rate it a strong buy, 1 a buy, 2 a hold, 0 a sell and 0 a strong sell, a consensus of buy. Ratings are opinions, not a recommendation from Quotelinks.
What is Prestige Consumer Healthcare's EPS forecast?
Analysts forecast $4.57 per share for FY2027 (range $4.45 to $4.63); for FY2028 the estimate is $5.08.
What is Prestige Consumer Healthcare's revenue forecast?
The average revenue estimate for FY2027 is $1.3 billion, growth of 17.0%; for FY2028 it is $1.4 billion.
When does Prestige Consumer Healthcare report earnings?
Prestige Consumer Healthcare is expected to report results for the quarter ending September 30, 2026 on November 5, 2026 before the market opens; the EPS estimate is $1.06.
Does Prestige Consumer Healthcare usually beat earnings estimates?
Prestige Consumer Healthcare reported EPS at or above the analyst estimate in 7 of the last 12 quarters.